Eisai Asks U.S. Court Of Appeals To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
This article was originally published in PharmAsia News
Executive Summary
Eisai says the U.S. Drug Enforcement Administration scheduling delay – 10 months after U.S. FDA approval and seven months after the U.S. Department of Health and Human Services submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.